{
    "pmid": "41454916",
    "title": "Downregulation of the lncRNA PGM5P4-AS1 predicts poor prognosis and drives breast cancer progression through miR-3664-5p/KLF9.",
    "abstract": "Accumulating evidence suggests that deregulated long non-coding RNAs (lncRNAs) drive breast cancer (BRCA) progression. This study investigated the expression profile and mechanism of PGM5P4 antisense RNA 1 (PGM5P4-AS1) in BRCA. The differentially expressed lncRNAs in BRCA were identified using the GEO dataset. Cancer and adjacent tissues were obtained from BRCA patients. Real-time quantitative polymerase chain reaction was used to quantify the expression of PGM5P4-AS1, microRNA (miR)-3664-5p, and Kr√ºppel-like factor 9 (KLF9). The Chi-squared test was used to assess the clinicopathological correlation of PGM5P4-AS1. Kaplan-Meier curves and Cox regression were used to evaluate their prognostic significance. Cell Counting Kit-8 kits, flow cytometry, and Transwell assays were used to assess cell proliferation, migration, invasion, and apoptosis. Dual-luciferase reporter and RNA immunoprecipitation assays were used to analyze the gene-target interactions. PGM5P4-AS1 downregulation in BRCA was consistently documented across three GEO datasets. In BRCA cancer tissues, both PGM5P4-AS1 and KLF9 were significantly downregulated, whereas miR-3664-5p was noticeably upregulated. A reduction in PGM5P4-AS1 was associated with tumor differentiation, tumor node metastasis staging, and lymph node metastasis. Low PGM5P4-AS1 expression independently predicts poor survival. Further, miR-3664-5p noticeably reverses the suppression of cell proliferation, migration, and invasion, as well as the promotion of apoptosis, induced by PGM5P4-AS1 overexpression. Mechanistically, miR-3664-5p targets PGM5P4-AS1/KLF9 directly, and KLF9 silencing reverses the cellular function inhibition caused by miR-3664-5p downregulation. This study first shows that decreased PGM5P4-AS1 in BRCA patients links to poor prognosis, promotes malignancy via miR-3664-5p/KLF9 axis, offering new therapy and prognosis in sight.",
    "disease": "breast cancer",
    "clean_text": "downregulation of the lncrna pgm p as predicts poor prognosis and drives breast cancer progression through mir p klf accumulating evidence suggests that deregulated long non coding rnas lncrnas drive breast cancer brca progression this study investigated the expression profile and mechanism of pgm p antisense rna pgm p as in brca the differentially expressed lncrnas in brca were identified using the geo dataset cancer and adjacent tissues were obtained from brca patients real time quantitative polymerase chain reaction was used to quantify the expression of pgm p as microrna mir p and kr ppel like factor klf the chi squared test was used to assess the clinicopathological correlation of pgm p as kaplan meier curves and cox regression were used to evaluate their prognostic significance cell counting kit kits flow cytometry and transwell assays were used to assess cell proliferation migration invasion and apoptosis dual luciferase reporter and rna immunoprecipitation assays were used to analyze the gene target interactions pgm p as downregulation in brca was consistently documented across three geo datasets in brca cancer tissues both pgm p as and klf were significantly downregulated whereas mir p was noticeably upregulated a reduction in pgm p as was associated with tumor differentiation tumor node metastasis staging and lymph node metastasis low pgm p as expression independently predicts poor survival further mir p noticeably reverses the suppression of cell proliferation migration and invasion as well as the promotion of apoptosis induced by pgm p as overexpression mechanistically mir p targets pgm p as klf directly and klf silencing reverses the cellular function inhibition caused by mir p downregulation this study first shows that decreased pgm p as in brca patients links to poor prognosis promotes malignancy via mir p klf axis offering new therapy and prognosis in sight"
}